J&J to build $1bn US CGT manufacturing site in Pennsylvania

Core Insights - Johnson & Johnson (J&J) has selected Pennsylvania for a new $1 billion cell therapy manufacturing facility, aligning with the Trump administration's push to onshore drug production in the US amid increasing global competition [1] - The new facility is expected to create over 500 skilled biomanufacturing jobs and 4,000 construction positions, marking J&J's eleventh site in Pennsylvania [2] - J&J's current cell therapy product, Carvykti, generated $1.9 billion in global sales in FY2025, with forecasts predicting sales of $7.8 billion by 2031 [3] Manufacturing Expansion - The Pennsylvania facility is part of J&J's broader $55 billion initiative to expand its manufacturing footprint in the US, which includes a $2 billion biologics production facility under construction in North Carolina [4] - J&J's decision to onshore manufacturing reflects a trend in the pharmaceutical industry, with companies aligning their operations with governmental goals, particularly in emerging biotech hubs like North Carolina and Virginia [6] Industry Trends - The approach to cell and gene therapies varies among pharmaceutical companies; while J&J is investing in cell therapy, others like Takeda have shifted focus away from this modality [7] - Conversely, companies such as Eli Lilly are actively pursuing cell and gene therapy opportunities, evidenced by significant deals in this area [8]